80 related articles for article (PubMed ID: 20651335)
41. Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines.
Kojima K; Fujino Y; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2013; 75(6):727-31. PubMed ID: 23337362
[TBL] [Abstract][Full Text] [Related]
42. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.
Krejci P; Salazar L; Kashiwada TA; Chlebova K; Salasova A; Thompson LM; Bryja V; Kozubik A; Wilcox WR
PLoS One; 2008; 3(12):e3961. PubMed ID: 19088846
[TBL] [Abstract][Full Text] [Related]
43. [Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
Lü SQ; Yang JM; Huang CM; Xu XQ; Zhou H; Song NX; Wang JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):869-73. PubMed ID: 21867604
[TBL] [Abstract][Full Text] [Related]
44. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
45. Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Sanacora S; Urdinez J; Chang TP; Vancurova I
Biochem Biophys Res Commun; 2015 May; 460(2):375-9. PubMed ID: 25791477
[TBL] [Abstract][Full Text] [Related]
46. [Screening drugs for regulating tissue factor gene expression].
Yang Y; Yan FZ; Yan JS; Zhao J; Li WP; Chen XY; Jin J; Rao SM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):207-10. PubMed ID: 21362253
[TBL] [Abstract][Full Text] [Related]
47. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
[TBL] [Abstract][Full Text] [Related]
48. Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas.
Larson A; Cook JR
Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):322-5. PubMed ID: 18528286
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.
Pollett JB; Trudel S; Stern D; Li ZH; Stewart AK
Blood; 2002 Nov; 100(10):3819-21. PubMed ID: 12393593
[TBL] [Abstract][Full Text] [Related]
50. Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency.
Stessman HA; Mansoor A; Linden MA; Van Ness B; Baughn LB
Leuk Lymphoma; 2014 Jan; 55(1):220-2. PubMed ID: 23734619
[No Abstract] [Full Text] [Related]
51. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
52. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91.
Cirone M; Di Renzo L; Lotti LV; Conte V; Trivedi P; Santarelli R; Gonnella R; Frati L; Faggioni A
PLoS One; 2012; 7(3):e31732. PubMed ID: 22412839
[TBL] [Abstract][Full Text] [Related]
53. Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Lupov IP; Voiles L; Han L; Schwartz A; De La Rosa M; Oza K; Pelloso D; Sahu RP; Travers JB; Robertson MJ; Chang HC
Blood; 2011 Dec; 118(23):6097-106. PubMed ID: 21998209
[TBL] [Abstract][Full Text] [Related]
54. Measurement of FGFR3 signaling at the cell membrane via total internal reflection fluorescence microscopy to compare the activation of FGFR3 mutants.
Hartl I; Brumovska V; Striedner Y; Yasari A; Schütz GJ; Sevcsik E; Tiemann-Boege I
J Biol Chem; 2023 Feb; 299(2):102832. PubMed ID: 36581204
[TBL] [Abstract][Full Text] [Related]
55. Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound.
Saliev T; Feril LB; Ogawa K; Watanabe A; Begimbetova D; Molkenov A; Alimbetov D; Tachibana K
Med Sci Monit; 2016 Dec; 22():5049-5057. PubMed ID: 28003640
[TBL] [Abstract][Full Text] [Related]
56. Hyperthermia enhances bortezomib-induced apoptosis in human white blood cancer cells.
Saliev T; Feril LB; Begimbetova D; Baiskhanova D; Klodzinskyi A; Bobrova X; Aipov R; Baltabayeva T; Tachibana K
J Therm Biol; 2017 Jul; 67():9-14. PubMed ID: 28558940
[TBL] [Abstract][Full Text] [Related]
57. Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis.
Liu B; Ding J; Liu Y; Wu J; Wu X; Chen Q; Li W
J Comput Aided Mol Des; 2023 Jul; 37(7):325-338. PubMed ID: 37269435
[TBL] [Abstract][Full Text] [Related]
58. Genetic and molecular targets in lymphoma: implications for prognosis and treatment.
Bachegowda LS; Barta SK
Future Oncol; 2014 Dec; 10(15):2509-28. PubMed ID: 25525858
[TBL] [Abstract][Full Text] [Related]
59. Widespread epidermal nevus with a postzygotic FGFR3 mutation.
Doi H; Matsuo R; Mizumoto T; Hashimoto Y; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Aug; 44(8):e186-e187. PubMed ID: 28664990
[No Abstract] [Full Text] [Related]
60. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer.
Reed JC
Adv Pharmacol; 1997; 41():501-32. PubMed ID: 9204157
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
